Advances Commercialization, Expands Strategic Partnerships and Accelerates Biopharmaceutical Platform Validation
Dyadic to host earnings call on
“During the third quarter, we reached a key commercialization milestone for our animal-free protein portfolio, advancing market adoption through initial product sales and growing customer engagement across the food, life sciences, and biopharmaceutical sectors,” said
“Concurrently, partner-led commercialization is building momentum.
Recent Company Developments
Commercial Products & Market Adoption
First Direct Commercial Product Sales: During the third quarter, Dyadic recorded its first direct commercial product sales, primarily of recombinant transferrin and DNase I. Although initial sales were not material in amount, they are a milestone as they establish a direct-product revenue channel, alongside existing and potential partner-generated license, milestone and profit-sharing or royalty economics.
Expanded OEM Distribution: Integrated Biotherapeutics (IBT Bioservices) launched an initial portfolio of six Dyadic-produced research-use-only recombinant protein products through its distribution network. The companies are evaluating additional offerings, extending Dyadic’s potential reach across research, diagnostics, reagent and cell culture applications.
Growing Customer Engagement: Sampling requests and customer evaluations increased for human and bovine transferrin and other recombinant proteins. Dyadic is supporting customer testing and qualification with the objective of converting these engagements into repeat purchases and sustained product demand.
Proliant AlbuFree™ Product Commercialization and Expansion:
Second Commercial Chymosin Demonstrates Dapibus™ Versatility: In
Strategic Partnerships, Licensing & Product Development
Advancing Alpha-Lactalbumin Toward Commercialization: Advanced collaboration activities with
Expanding Strategic Licensing Opportunities: Continued discussions with additional global companies regarding potential licensing, development and commercial arrangements involving alpha-lactalbumin and other animal-free proteins, as well as product collaborations and broader strategic opportunities involving C1, Dapibus and the Company’s recombinant protein portfolio. These discussions are intended to leverage partners’ resources, manufacturing capabilities and market access to advance higher-value products, including alpha-lactalbumin and transferrin, while creating opportunities for upfront fees, milestones and ongoing commercial participation.
Broader Nutrition Protein Portfolio: Initiated development of recombinant bovine lactoferrin, complementing the Company’s human lactoferrin and alpha-lactalbumin programs and extending its portfolio of animal-free nutritional and functional proteins.
C1 Biopharmaceutical Platform – Advancing Global Vaccine and Antibody Programs
Gates Foundation Programs Advance to Animal Studies: Under its approximately
Accelerating C1 Biopharmaceutical Validation and Adoption: Continued to advance multiple vaccine and monoclonal antibody programs through preclinical development, including ongoing animal studies evaluating ebolavirus and other vaccine candidates conducted in collaboration with Fondazione Biotecnopolo di Siena (FBS) and the European Vaccines Hub (EVH). Dyadic also continued advancing programs with
Financial Highlights
Cash Position: As of
Revenue: Total revenue for the three months ended
Cost of Revenue: Total cost of revenue for the three months ended
R&D Expenses: Research and development expenses for the three months ended
G&A Expenses: General and administrative expenses for the three months ended
Loss from Operations: Loss from operations for the three months ended
Other Income (Expenses), Net: For the three months ended
Net Loss: Net loss for the three months ended
Conference Call Information
Date:
Time:
Dial-in numbers: Toll Free: +1-877-407-9219 / +1 412-652-1274
Conference ID: 13761286
Webcast Link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=IKih8Wc8
An archive of the webcast will be available within 24 hours after completion of the live event and will be accessible on the Investor Relations section of the Company’s website at www.dyadic.com. To access the replay of the webcast, please follow the webcast link above.
About Dyadic Applied BioSolutions
Dyadic Applied BioSolutions is a global biotechnology company that uses its proprietary microbial platforms to produce recombinant proteins that are sold or licensed to partners across the life sciences, food and nutrition, and bio-industrial markets. These high-quality proteins are designed to enable customers to develop more efficient, scalable, and sustainable products. Dyadic’s Dapibus™ and C1 expression systems support flexible, cost-effective manufacturing, and are the foundation of a growing portfolio of commercial and partnered programs.
For more information, please visit http://www.dyadic.com.
Safe Harbor Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, including those regarding Dyadic International’s expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, such as the success of our clinical trial and interest in our protein production platforms, our research projects and third-party collaborations, as well as the availability of necessary funding. Forward-looking statements generally can be identified by use of the words “expect,” “should,” “intend,” “anticipate,” “will,” “project,” “may,” “might,” “potential,” or “continue” or other similar terms or variations of them. Forward-looking statements involve many risks, uncertainties or other factors beyond Dyadic’s control. These factors include, but are not limited to, the following: (i) our history of net losses, and management’s related conclusion that there is substantial doubt about our ability to continue as a going concern for the 12 months following November 12, 2026; (ii) market and regulatory acceptance of our microbial protein production platforms and other technologies; (iii) failure to commercialize our microbial protein production platforms or our other technologies; (iv) competition, including from alternative technologies; (v) the results of nonclinical studies and clinical trials; (vi) our capital needs and the dilutive impact of a capital raise to mitigate our going-concern risk; (vii) changes in global economic and financial conditions; (viii) our reliance on information technology; (ix) our dependence on third parties; (x) government regulations and environmental, social and governance issues; (xi) intellectual property risks; and (xii) our ability to comply with the listing standards of the Nasdaq Stock Market LLC. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled “Risk Factors” in Dyadic’s annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic’s periodic filings with the SEC, which are accessible on the SEC’s website and at www.dyadic.com. All forward-looking statements speak only as of the date made, and except as required by applicable law, Dyadic assumes no obligation to publicly update any such forward-looking statements for any reason after the date of this press release to conform these statements to actual results or to changes in our expectations.
Contact:
Dyadic International, Inc.
Ping Rawson
Chief Financial Officer
Phone: (561) 743-8333
Email: ir@dyadic.com
CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) | ||||||||||||||||
| Three months ended | Nine months ended | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenue: | ||||||||||||||||
| Research and development revenue | $ | 162,318 | $ | 350,046 | $ | 689,794 | $ | 746,595 | ||||||||
| Grant revenue | 276,372 | 814,571 | 1,600,990 | 1,528,224 | ||||||||||||
| License and milestone revenue | 10,411 | — | 230,411 | 250,000 | ||||||||||||
| Total revenue | 449,101 | 1,164,617 | 2,521,195 | 2,524,819 | ||||||||||||
| Costs and expenses: | ||||||||||||||||
| Costs of research and development revenue | 109,475 | 254,753 | 572,954 | 529,690 | ||||||||||||
| Costs of grant revenue | 265,640 | 769,250 | 1,578,166 | 1,405,562 | ||||||||||||
| Research and development | 429,945 | 571,872 | 1,238,635 | 1,696,230 | ||||||||||||
| General and administrative | 1,450,750 | 1,481,356 | 4,895,944 | 4,514,324 | ||||||||||||
| Foreign currency exchange (gain) loss, net | 5,656 | 12,755 | 4,758 | 35,925 | ||||||||||||
| Total costs and expenses | 2,261,466 | 3,089,986 | 8,290,457 | 8,181,731 | ||||||||||||
| Loss from operations | (1,812,365 | ) | (1,925,369 | ) | (5,769,262 | ) | (5,656,912 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Interest income | 19,327 | 63,467 | 116,223 | 201,052 | ||||||||||||
| Interest expense | (64,556 | ) | (85,934 | ) | (193,377 | ) | (264,633 | ) | ||||||||
| Interest expense - related party | (44,974 | ) | (28,176 | ) | (134,719 | ) | (76,872 | ) | ||||||||
| Change in fair value of warrant liability, net of issuance costs of | 545,527 | — | 545,527 | — | ||||||||||||
| Total other income (expense), net | 455,324 | (50,643 | ) | 333,654 | (140,453 | ) | ||||||||||
| Net loss | $ | (1,357,041 | ) | $ | (1,976,012 | ) | $ | (5,435,608 | ) | $ | (5,797,365 | ) | ||||
| Basic and diluted net loss per common share | $ | (0.04 | ) | $ | (0.06 | ) | $ | (0.15 | ) | $ | (0.18 | )(1) | ||||
| Basic and diluted weighted-average common shares outstanding | 38,291,651 | 34,081,115(1) | 37,049,720 | 31,423,446(1) | ||||||||||||
See Notes to Consolidated Financial Statements in Item 1 of Dyadic’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2026.
(1) The 2025 weighted-average shares outstanding and net loss per share have been revised to correct an immaterial error in the computation. The revision had no impact on net loss.
CONSOLIDATED BALANCE SHEETS | ||||||||
2026 | 2025 | |||||||
| (Unaudited) | (Audited) | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 3,926,803 | $ | 4,622,331 | ||||
| Short-term investment securities | 646,987 | 2,698,661 | ||||||
| Restricted cash | 1,464,821 | 1,231,168 | ||||||
| Interest receivable | 7,472 | 35,129 | ||||||
| Accounts receivable | 1,523,052 | 1,090,297 | ||||||
| Prepaid expenses and other current assets | 299,162 | 219,067 | ||||||
| Total current assets | 7,868,297 | 9,896,653 | ||||||
| Non-current assets: | ||||||||
| Operating lease right-of-use asset, net | 55,627 | 38,535 | ||||||
| Other assets | 9,750 | 10,537 | ||||||
| Total assets | $ | 7,933,674 | $ | 9,945,725 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,522,210 | $ | 852,024 | ||||
| Accrued expenses | 1,389,740 | 967,974 | ||||||
| Deferred research and development obligations | 1,584,920 | 1,730,852 | ||||||
| Operating lease liability | 50,536 | 34,621 | ||||||
| Accrued interest | 60,000 | 60,000 | ||||||
| Accrued interest - related party | 41,800 | 41,800 | ||||||
| Total current liabilities | 4,649,206 | 3,687,271 | ||||||
| Non-current liabilities: | ||||||||
| Convertible notes, net of issuance costs | 2,975,681 | 2,962,304 | ||||||
| Convertible notes, net of issuance costs - related party | 2,073,059 | 2,063,740 | ||||||
| Warrant liability | 813,424 | — | ||||||
| Total liabilities | 10,511,370 | 8,713,315 | ||||||
| Commitments and contingencies (Note 5) | ||||||||
| Stockholders’ equity: | ||||||||
| Preferred stock, | ||||||||
| Authorized shares - 5,000,000; none issued and outstanding | — | — | ||||||
| Common stock, | ||||||||
| Authorized shares - 100,000,000; issued shares - 52,344,705 and 48,441,300, outstanding shares - 40,091,203 and 36,187,798 as of | 52,345 | 48,442 | ||||||
| Additional paid-in capital | 115,186,590 | 113,564,991 | ||||||
| (18,929,915 | ) | (18,929,915 | ) | |||||
| Accumulated deficit | (98,886,716 | ) | (93,451,108 | ) | ||||
| Total stockholders’ (deficit) equity | (2,577,696 | ) | 1,232,410 | |||||
| Total liabilities and stockholders’ equity | $ | 7,933,674 | $ | 9,945,725 | ||||
See Notes to Consolidated Financial Statements in Item 1 of Dyadic’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2026.
Source: 